be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Sven Zimmermann Joins MetrioPharm Management as CFO
MetrioPharm AG, a pharmaceutical develop...
Lycored Launches Video to Support Study Findings
Lycored, industry leaders in cultivating we...
Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Molecular Biology and Immunology of Cancer – R&D perspectives: ScanBalt Forum 2019, 24-25 September, Gdańsk (Poland)

All articles

Filters:

Show search box

2015-03-25

Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Green light for Novartis drug “Jakavi” for rare blood cancer treatment

Novartis drug “Jakavi” has been approved by the European Commission for the therapy of rare blood cancer, polycythemia vera. It is the first approved targeted drug for treatment of this disease and it gives hope for patients unresponsive to standard therapy with hydroxyurea.... Read more

Tags drug , cancer , eu , Novartis , targeted therapy , approval